Cerebrolysin patent for CADASIL treatment

ChangeBridge: Patent Grants - Peptides (C07K)

Published March 31st, 2026

Detected March 31st, 2026

Summary

USPTO granted patent US12589118B2 to Ever Neuro Pharma GmbH for a method of using cerebrolysin to reduce mortality in patients with CADASIL (cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy). The patent includes 15 claims and was filed on August 28, 2018.

View original document View source feed page

What changed

The USPTO granted patent US12589118B2 to Ever Neuro Pharma GmbH (inventors Stefan Winter and Herbert Mössler) covering the use of cerebrolysin preparations for prolonging the lifespan of CADASIL patients. The patent contains 15 claims and falls under CPC classifications including A61K 38/00, C07K 14/47, and A61P 25/28.

This patent grant is informational for pharmaceutical companies and healthcare providers researching or developing treatments for rare neurological conditions. No immediate compliance actions are required. Companies developing similar peptide-based treatments for vascular dementia or cerebrovascular diseases should review their Freedom to Operate positions to avoid potential infringement.

Source document (simplified)

← USPTO Patent Grants

Method of prolonging the lifespan of patients with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) using a cerebrolysin® preparation

Grant US12589118B2 Kind: B2 Mar 31, 2026

Assignee

EVER NUERO PHARMA GMBH

Inventors

Stefan Winter, Herbert Mössler

Abstract

Disclosed is cerebrolysin for use in reducing mortality in CADASIL (cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy) patients.